News

Melissa Long knows firsthand what it is like to battle isolation and depression as a teenage cancer survivor. Today, as a pediatric oncology nurse, she helps children and teens with cancer battle their disease while also using her own experience to help prepare them for possible late effects of treatment-especially the ‘invisible' emotional ones.

Juliana's Story

By

I had firmly put cancer in my rear view mirror seven-years prior. Yet here I was, hearing for the word "cancer" for the second time by the age of 26.

Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.

Treatment with bevacizumab (Avastin) plus chemotherapy resulted in a non-statistically significant improvement in overall survival (OS) of nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Are you looking for financial assistance with direct medical costs (co-pays, deductibles), related non-medical costs (transportation, gas, child care) or daily living expenses (rent, utilities)? With effort and persistence, you can find some help.

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy (IP), have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.

In this roundtable, representatives from Sharsheret, the Cancer Support Community, the Young Survival Coalition, and Living Beyond Breast Cancer discuss the impact of metastatic breast cancer.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, told attendees at the 8th International Prostate Cancer Congress, the decision to screen or not to screen boiled down to "using common sense, shared decision making, and choosing the right patients to screen."